Arbidol:: a broad-spectrum antiviral that inhibits acute and chronic HCV infection

被引:76
作者
Boriskin, Yury S.
Pecheur, Eve-Isabelle
Polyak, Stephen J. [1 ]
机构
[1] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA
[2] Univ Washington, Dept Microbiol, Seattle, WA 98195 USA
[3] Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA
[4] Univ Lyon 1, IFR128, F-69365 Lyon, France
[5] Univ Lyon 1, Inst Biol & Chim Proteines, UMR 5086, CNRS, F-69365 Lyon, France
[6] Inst Virol, Moscow, Russia
关键词
D O I
10.1186/1743-422X-3-56
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Arbidol (ARB) is an antiviral compound that was originally proven effective for treatment of influenza and several other respiratory viral infections. The broad spectrum of ARB anti-viral activity led us to evaluate its effect on hepatitis C virus (HCV) infection and replication in cell culture. Long-term ARB treatment of Huh7 cells chronically replicating a genomic length genotype Ib replicon resulted in sustained reduction of viral RNA and protein expression, and eventually cured HCV infected cells. Pre-treatment of human hepatoma Huh7.5.I cells with 15 mu M ARB for 24 to 48 hours inhibited acute infection with JFH-1 virus by up to 1000-fold. The inhibitory effect of ARB on HCV was not due to generalized cytotoxicity, nor to augmentation of IFN antiviral signaling pathways, but involved impaired virus-mediated membrane fusion. ARB's affinity for membranes may inhibit several aspects of the HCV lifecycle that are membrane-dependent.
引用
收藏
页数:9
相关论文
共 32 条
[1]   Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes [J].
Bartosch, B ;
Dubuisson, J ;
Cosset, FL .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (05) :633-642
[2]   Antiviral chemotherapeutic agents against respiratory viruses: where are we now and what's in the pipeline? [J].
Brooks, MJ ;
Sasadeusz, JJ ;
Tannock, GA .
CURRENT OPINION IN PULMONARY MEDICINE, 2004, 10 (03) :197-203
[3]   Synthesis and in vitro anti-hepatitis B virus activities of some ethyl 6-bromo-5-hydroxy-1H-indole-3-carboxylates [J].
Chai, HF ;
Zhao, YF ;
Zhao, CS ;
Gong, P .
BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (04) :911-917
[4]   Virus morphogenesis and viral entry as alternative targets for novel hepatitis C antivirals [J].
Chapel, Cynthia ;
Zitzmann, Nicole ;
Zoulim, Fabien ;
Durantel, David .
FUTURE VIROLOGY, 2006, 1 (02) :197-209
[5]  
Chen Stephen L, 2006, Int J Med Sci, V3, P47
[6]   Use of the MagNA pure LC automated nucleic acid extraction system followed by real-time reverse transcription-PCR for ultrasensitive quantitation of hepatitis C virus RNA [J].
Cook, L ;
Ng, KW ;
Bagabag, A ;
Corey, L ;
Jerome, KR .
JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (09) :4130-4136
[7]   JAK-STAT PATHWAYS AND TRANSCRIPTIONAL ACTIVATION IN RESPONSE TO IFNS AND OTHER EXTRACELLULAR SIGNALING PROTEINS [J].
DARNELL, JE ;
KERR, IM ;
STARK, GR .
SCIENCE, 1994, 264 (5164) :1415-1421
[8]   Challenges and successes in developing new therapies for hepatitis C [J].
De Francesco, R ;
Migliaccio, G .
NATURE, 2005, 436 (7053) :953-960
[9]   S-adenosylmethionine and betaine correct hepatitis C virus induced inhibition of interferon signaling in vitro [J].
Duong, FHT ;
Christen, V ;
Filipowicz, M ;
Heim, MH .
HEPATOLOGY, 2006, 43 (04) :796-806
[10]   Mechanism of action of interferon and ribavirin in treatment of hepatitis C [J].
Feld, JJ ;
Hoofnagle, JH .
NATURE, 2005, 436 (7053) :967-972